{"organizations": [], "uuid": "1b1167d3c70191641f2ed1373903d4b3b385b10c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-fda-accepts-novartis-submission-of/brief-fda-accepts-novartis-submission-of-biosimilar-version-of-humira-idUSFWN1PA0O9", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA accepts Novartis submission of biosimilar version of Humira", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-16T08:06:00.000+02:00", "replies_count": 0, "uuid": "1b1167d3c70191641f2ed1373903d4b3b385b10c"}, "author": "", "url": "https://www.reuters.com/article/brief-fda-accepts-novartis-submission-of/brief-fda-accepts-novartis-submission-of-biosimilar-version-of-humira-idUSFWN1PA0O9", "ord_in_thread": 0, "title": "BRIEF-FDA accepts Novartis submission of biosimilar version of Humira", "locations": [], "entities": {"persons": [{"name": "michael shields", "sentiment": "none"}], "locations": [{"name": "humira", "sentiment": "none"}, {"name": "humira", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "brief-fda", "sentiment": "negative"}, {"name": "novartis", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "humira reuters", "sentiment": "none"}, {"name": "novartis ag", "sentiment": "none"}, {"name": "bla", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 16, 2018 / 6:07 AM / Updated 12 minutes ago BRIEF-FDA accepts Novartis submission of biosimilar version of Humira Reuters Staff \nJan 16 (Reuters) - Novartis AG: \n* SANDOZ REGULATORY SUBMISSION FOR PROPOSED BIOSIMILAR ADALIMUMAB ACCEPTED BY FDA \n* US FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTED ITS BIOLOGICS LICENSE APPLICATION (BLA), SUBMITTED UNDER THE 351 (K) PATHWAY, FOR PROPOSED BIOSIMILAR ADALIMUMAB TO THE REFERENCE MEDICINE, HUMIRA \n* ‍DATA PACKAGE PROVIDED IS EXPECTED TO DEMONSTRATE THAT SANDOZ PROPOSED BIOSIMILAR ADALIMUMAB MATCHES REFERENCE BIOLOGIC MEDICINE IN TERMS OF SAFETY, EFFICACY AND QUALITY​ Source text for Eikon: Further company coverage: (Reporting By Michael Shields)", "external_links": [], "published": "2018-01-16T08:06:00.000+02:00", "crawled": "2018-01-16T08:28:30.004+02:00", "highlightTitle": ""}